4
Changes in Ownership
Fulcrum Therapeutics, Inc. Filed Acc 0000899243-22-013881
Director sold 94,251 shares at an average $24.16 ($2,276,684)
- Director acquired 94,251 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Gould Robert J Director | 2022-04-01 | Option exercise | +34,464 | $7.84 | $270,198 | 541,094 | D |
| Gould Robert J Director | 2022-04-01 | Sale | −34,464 | $24.03 | $828,160 | 506,630 | D |
| Gould Robert J Director | 2022-04-04 | Option exercise | +7,235 | $7.84 | $56,722 | 513,865 | D |
| Gould Robert J Director | 2022-04-04 | Sale | −7,235 | $24.02 | $173,749 | 506,630 | D |
| Gould Robert J Director | 2022-04-05 | Option exercise | +52,552 | $7.84 | $412,008 | 559,182 | D |
| Gould Robert J Director | 2022-04-05 | Sale | −52,552 | $24.26 | $1,274,775 | 506,630 | D |
| Derivatives | |||||||
| Gould Robert J Director | 2022-04-01 | Option exercise · Stock Option (right to buy) | −34,464 | 289,998 | D | ||
| Gould Robert J Director | 2022-04-04 | Option exercise · Stock Option (right to buy) | −7,235 | 282,763 | D | ||
| Gould Robert J Director | 2022-04-05 | Option exercise · Stock Option (right to buy) | −52,552 | 230,211 | D | ||
| Open-market sales · 94,251 sh · avg $24.16 · $2,276,684 | |||||||
Loading xslF345X03/doc4.xml…